| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-12-05 | Jakavi®/Jakafi® - INC424 (ruxolitinib) | polycythaemia vera | 3 | Novartis (Switzerland) | Rare diseases |
| 2015-12-05 | Jakafi® - INC424 (ruxolitinib) | myelofibrosis | 3 | Novartis (Switzerland) | Cancer - Oncology - Blood diseases - Hematological diseases |
| 2015-12-05 | AG-120 - isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor | advanced hematologic malignancies including elapsed or refractory acute myeloid leukemia (AML), untreated AML and other IDH1-mutated positive hematologic malignancies | 1 | Agios Pharmaceuticals (USA - MA) | Cancer - Oncology - Rare diseases |
| 2015-12-05 | Gazyva™ (obinutuzumab - GA101) | chronic lymphocytic leukemia (CLL) | 3 | Genentech, a member of the Roche Group (USA - Switzerland) | Cancer - Oncology |
| 2015-12-05 | cytotoxic T lymphocytes (CTL) activated against Wilms' Tumor 1 (WT1-CTL) | relapsed-refractory multiple myeloma | 1 | Atara Biotherapeutics (USA - CA) Memorial Sloan Kettering Cancer Center (USA - NY) | Cancer - Oncology |
| 2015-12-05 | GMI-1271 | acute myeloid leukemia (AML) | 1 | GlycoMimetics (USA - Md) | Cancer - Oncology |
| 2015-12-05 | IMO-8400 - antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9 | Waldenstrom's macroglobulinemia | 1-2 | Idera Pharmaceuticals (USA - CA) | Cancer - Oncology - Rare diseases |
| 2015-12-04 | citarinostat (ACY-241) and nivolumab | non-small cell lung cancer (NSCLC) | 1b | Acetylon Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2015-12-04 | BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) | diffuse large B-cell lymphoma (DLBCL) | 2 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2015-12-04 | ARC-520 | hepatitis B | preclinical | Arrowhead Research Corporation (USA - CA) | Infectious diseases |
| 2015-12-02 | NW-3509 | schizophrenia | 2 | Newron Pharmaceuticals (Italy) | CNS diseases - Mental diseases |
| 2015-12-01 | tumor growth factor kinoid | preclinical | Neovacs (France) | Cancer - Oncology | |
| 2015-12-01 | NI-0501 | hemophagocytic lymphohistiocytosis (HLH) | 2 | NovImmune (Switzerland) | Rare diseases - Immunological diseases |
| 2015-12-01 | PledOx™ | reduction of side effects caused by the chemotherapy FOLFOX in patients treated for metastatic colorectal cancer | 2 | PledPharma (Sweden) | Cancer - Oncology |
| 2015-12-01 | Ryzodeg® | type 2 diabetes | Novo Nordisk (Denmark) | Metabolic diseases | |
| 2015-12-01 | N91115 (S-nitrosoglutathione reductase inhibitor) with lumacaftor/ivacaftor (Orkambi™) | cystic fibrosis in patients who have two copies of the F508del mutation | 2 | Nivalis Therapeutics (USA - CO) | Rare diseases - Genetic diseases |
| 2015-12-00 | pidilizumab (MDV9300) | relapsed or refractory diffuse large B-cell lymphoma | 2 | Medivation (USA - CA) now Pfizer (USA - NY) | Cancer - Oncology |
| 2015-12-00 | pidilizumab (MDV9300) | relapsed or refractory diffuse large B-cell lymphoma | 2 | Medivation (USA - CA) now Pfizer (USA - NY) | Cancer - Oncology |
| 2015-11-30 | Clevegen® | Faron Pharmaceuticals (Finland) | Cancer - Oncology | ||
| 2015-11-30 | INT-767 | 1 | Intercept Pharmaceuticals (USA - NY) |
